跳至主要内容
临床试验/JPRN-jRCT2052210072
JPRN-jRCT2052210072进行中(未招募)3 期

Confirmatory clinical trial of silk-elastin sponge (P47K-WAS) for patients with skin defects

Kawabata Shingo0 个研究点目标入组 25 人开始时间: 2021年8月26日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • [Case of chronic wounds]
  • 1. The total wound size after 4 weeks of conventional treatment was still more than 50% of the wound size at the first visit.
  • 2. The wound area (long times short diameter) after debridement ranged from 2cm^2 to 25cm^2.
  • 3. When the wound was covered by the P47K-WAS, it could be sealed by woun dressing.
  • 4. When the wound was present at the same time as the target wound, there was healthy skin between the wounds.
  • 5. There was no local infection in the wound.
  • 6. The proportion of the area that exposed bone was <10% of the total wound area.
  • 7. In the case of chronic wounds on the lower legs, feet, and toes, the skin perfusion pressure of the affected leg exceeded 30mm Hg.
  • 8. Those that can be diagnosed as diabetic ulcers, venous stasis uclers, decubitus, etc. as background diseases of the wound.
  • [Case of acute wounds]
  • 1. The following wounds, which had no intrinsic factors that prolong wound healing and were considered to require wound bed preparation (WBP).
  • Complex wound, the burn that was higher than invasion depth grade II, the local infection wound that were considered to be controllable and soothing.
  • 2. The wound area (long times short diameter) after debridement ranged from 2cm^2 to 100cm^2.
  • 3. When the wound was covered by the P47K-WAS, it could be sealed by wound dressing.
  • 4. When the wound was present at the same time as the target wound, there was healthy skin between the wounds.
  • 5. There was no local infection in the wound.
  • 6. The proportion of the area that exposed bone was <10% of the total wound area.

排除标准

  • 1. The patient was < 20 years old when he/she consented to participate in the trial.
  • 2. Womans that fell under any of the following.
  • . Women who did not consent to use contraception during the trial
  • . Women who were or could be pregnant
  • . Women who were nursing
  • 3. Patients with previous histories of allergy against silk, urethane, and other reagents used in the trial, including anesthetics and disinfectant
  • 4. Patients with any of the following conditions:
  • . Poorly controlled diabetes (>10% of HbA1c in the latest laboratory findings within 28 days before enrollment)
  • . Hypoalbuminemia (< 2 g/dL)
  • . Patient was being treated for malignancy.
  • . Patient required continuous systemic administration of steroids (dose exceeding an equivalent predonisolone dose of 10mg/day).
  • 5. Patients participated in another clinical trial within 3 months before enrollment.
  • 6. Wounds that were difficult to do decompression relief.
  • 7. Patients participated in this trial and were administered the investigational device.
  • 8. Patients who were not able to consent in writing to participate in the trial.
  • 9. Patients who were considered by an investigator or sub-investigator to be inappropriate for inclusion in the trial.

研究者

发起方
Kawabata Shingo

相似试验